Planova™我们的活动

Novel Planova™ Filter - Planova S20N

Kazuya Kobayashi
Manager, Global Sales & Customer Services Department
Bioprocess Division
Asahi Kasei Medical
23rd Planova Workshop
Oct 6, 2022 to Oct 7, 2022
New York City

• Kazuya Kobayashi_NY WS Presentation_S20N.pdf

Challenges of implementing virus filtration in continuous manufacturing

Daniel Strauss, Ph.D., Principal Scientist Science and Technology
Asahi Kasei Bioprocess America
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA

• C-6 AsahiKaseiBioprocessAmerica.pdf

Evaluating the Impact on Viral Clearance of Multiple Unplanned Interruptions During Virus Removal Filtration

Kevin K. Okimura, Senior Manager Outsourced Manufacturing
Portola Pharmaceuticals
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA

• C-4-PortolaPharmaceuticals.pdf

Clearing the way for viral clearance

David Cetlin, Founder/C.E.O.
MockV Solutions
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA

• C-3-MockVSolutions.pdf

Of future biotechnology options and the central role of nanofiltrarion

Andreas Wieser, D (I FH), Senior Laboratory Associate Global Pathogen Safety
Shire
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA

• C-2-Shire.pdf

Meeting PlanovaTM and Selecting BioEX for Our Monoclonal Antibody Manufacturing Process

Yumiko Masuda, Scientist Biologics Technology Research Laboratories Biologics Division
Daiichi Sankyo
Meeting Planova and Selecting BioEX for Our Monoclonal Antibody Manufacturing Process
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA

• C-1-DaiichiSankyo.pdf

Challenges & Strategies for Viral Filtration

Matt (Mingjiang) Luo, Ph.D., Executive Director Downstream Process Development and Haikuan Liu, Ph.D., Associate Director Downstream Process Development
Wuxi Biologics (Shanghai)
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA

• B-5-6-WuXiBiologics.pdf

A Case Study: Evaluation of the Effect of Process Pause and Pressure Variation on Planova 20N Virus Filter

Samuel Vollert, Process Development Scientist I Downstream Process Development
Patheon (Thermo Fisher Scientific)
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA

• B-1-ThermoFisherScientific.pdf

Clarification Impurities Impact Viral Filtration of a Therapeutic Antibody

Ryan Zolyomi, Senior Development Associate Isolation & Purification Biological Development
Bayer U.S.
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA

• B-4-BayerUS.pdf

Visualization of behavior of virus and proteins in Planova membrane filters using advanced microscope system with confocal optics

Takayuki Nishizaka, Ph.D., Professor, Department of Physics
Gakushuin University
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA

• A-6-GakushuinUniversity.PDF

Different apparent Size of Parvoviruses determined by Virus Filtration

Thomas Nowak, Ph.D., Senior Manager Pathogen Safety
CSL Behring
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA

• A-5-CSLBehring.pdf

Establishing a Virus Filter Design Space - Impact of Process Interruption on Parvovirus Retention

Ashlee Smith, Associate Scientist BioTherapeutics Development - API; Discovery, Product Development & Supply
Janssen Research & Development
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA

• A-4-Janssen.pdf

Overview of Challenges in Virus Filtration: Principles and Applications

Tomoko Hongo-Hirasaki, Ph.D., Senior Scientist Evaluation and Analysis in Virus Filtration Bioprocess Division
Asahi Kasei Medical
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA

• A-3-AsahiKaseiMedical.pdf

A Review of Virus Filter Performance

Horst Ruppach, Ph.D., Director, Viral Clearance and Virology Biologics Testing Solutions
Charles River Laboratories
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA

• A-2_CharlesRiverLaboratories.pdf

Update on European Regulations

Johannes Blümel, Ph.D., Head of Virus Safety Section Department of Virology
Paul-Ehrlich-Institut
21st Planova Workshop
Oct 11, 2018 to Oct 12, 2018
San Francisco, CA, USA

• A-1_Paul-Ehrlich-Institut.pdf

Consistent and Reliable 100% Retrovirus Removal by Planova™ 20N filter: Demonstration of Robust Log Reduction (>6.0) by Co-spiking Study

Dayue Chen, Virology Group Bioprocess Research and Development, Eli Lilly and Company
14th Planova™ Workshop
Nov 9, 2011 to Nov 10, 2011
Cologne

• A_3 Eili Lilly.pdf

Virus Inactivation at Low pH: Impact of Buffers, pH Value, Protein Concentration and Temperature on the Inactivation of Retroviruses

Michael Dieterle, Associate Director Downstream Development, Boehringer Ingelheim GmbH&Co.KG
14th Planova™ Workshop
Nov 9, 2011 to Nov 10, 2011
Cologne

• B1_BI.pdf

Implementation of Quality by Design to Nanofiltration of Plasma Products

Monique Ollivier, Director, Process Development-Downstream & Analytics, Cytheris S.A.
14th Planova™ Workshop
Nov 9, 2011 to Nov 10, 2011
Cologne

• B4_LFB.pdf

FULL PLASTICS for a 1000L Disposable Production Line for Generic Antibody Manufacturing

Peter Rogge, Director, DSP Production, Rentschler Biotechnologie GmbH
14th Planova™ Workshop
Nov 9, 2011 to Nov 10, 2011
Cologne

New Concept of Integrity Test for Planova™ BioEX

Shinya Sekine, Manager, Technology Development Department, Asahi Kasei Medical Co., Ltd.
14th Planova™ Workshop
Nov 9, 2011 to Nov 10, 2011
Cologne

• B8_Asahi.pdf